These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 12497044)

  • 41. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects.
    Ribeiro FR; Jerónimo C; Henrique R; Fonseca D; Oliveira J; Lothe RA; Teixeira MR
    Clin Cancer Res; 2006 Jul; 12(13):3961-70. PubMed ID: 16818693
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Androgen receptor as a potential sign of prostate cancer metastasis.
    Lévesque MH; El-Alfy M; Cusan L; Labrie F
    Prostate; 2009 Nov; 69(15):1704-11. PubMed ID: 19670238
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early prostate cancer detected using expression of non-functional cytolytic P2X7 receptors.
    Slater M; Danieletto S; Gidley-Baird A; Teh LC; Barden JA
    Histopathology; 2004 Mar; 44(3):206-15. PubMed ID: 14987223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells.
    Ali TZ; Epstein JI
    Am J Surg Pathol; 2008 Dec; 32(12):1890-5. PubMed ID: 18813120
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues.
    Yousef GM; Stephan C; Scorilas A; Ellatif MA; Jung K; Kristiansen G; Jung M; Polymeris ME; Diamandis EP
    Prostate; 2003 Sep; 56(4):287-92. PubMed ID: 12858357
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical validity of proliferating cell nuclear antigen as an objective marker for evaluating biologic features in patients with untreated prostate cancer.
    Miyamoto S; Ito K; Kurokawa K; Suzuki K; Suzuki K; Yamanaka H
    Int J Urol; 2006 Jun; 13(6):767-72. PubMed ID: 16834658
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
    Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O
    Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tissue-based quantification of 8-hydroxy-2'-deoxyguanosine in human prostate biopsies using quantitative fluorescence imaging analysis.
    Richardson T; McCanse W; Casale GP; Huang D; Tian J; Elkahwaji JE; Lele S; Hemstreet GP
    Urology; 2009 Nov; 74(5):1174-9. PubMed ID: 19716591
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg.
    Scattoni V; Montironi R; Mazzucchelli R; Freschi M; Nava L; Losa A; Terrone C; Scarpa RM; Montorsi F; Pappagallo G; Rigatti P
    BJU Int; 2006 Jul; 98(1):54-8. PubMed ID: 16831143
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genomic DNA Methylation-Derived Algorithm Enables Accurate Detection of Malignant Prostate Tissues.
    Aref-Eshghi E; Schenkel LC; Ainsworth P; Lin H; Rodenhiser DI; Cutz JC; Sadikovic B
    Front Oncol; 2018; 8():100. PubMed ID: 29740534
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of the apoptotic calcium channel P2X7 in the glandular epithelium.
    Slater M; Danieletto S; Barden JA
    J Mol Histol; 2005 Mar; 36(3):159-65. PubMed ID: 15900405
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer.
    Schoenfield L; Jones JS; Zippe CD; Reuther AM; Klein E; Zhou M; Magi-Galluzzi C
    BJU Int; 2007 Apr; 99(4):770-4. PubMed ID: 17233800
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Biopsy technique and biopsy schemes for a first series of prostatic biopsies].
    Villers A; Mouton D; Rébillard X; Chautard D; Ruffion A; Staerman F; Cornud F
    Prog Urol; 2004 Apr; 14(2):144-53. PubMed ID: 15217126
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detection of preneoplasia in histologically normal prostate biopsies.
    Slater MD; Delprado WJ; Murphy CR; Barden JA
    Prostate Cancer Prostatic Dis; 2001; 4(2):92-96. PubMed ID: 12497044
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Markers for the development of early prostate cancer.
    Slater MD; Lauer C; Gidley-Baird A; Barden JA
    J Pathol; 2003 Mar; 199(3):368-77. PubMed ID: 12579539
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prostate biopsy: who, how and when. An update.
    Djavan B; Milani S; Remzi M
    Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.